KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
CONCLUSION: The specific KRAS mutation determines the responsiveness to anti-EGFR monoclonal antibody treatment, corresponding to reported clinical observations.
PMID: 24558511 [PubMed]
Source: Gastrointestinal Cancer Research - Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Erbitux | Gastroenterology | Genetics | Sarcomas | Study